Literature DB >> 30023097

Targeting minimal residual disease after surgery with molecular targeted therapy: the real path to a cure?

Katsuhiro Masago1, Shiro Fujita1, Yasushi Yatabe1.   

Abstract

Year:  2018        PMID： 30023097      PMCID： PMC6036056          DOI： 10.21037/jtd.2018.04.155

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  23 in total

1.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.

Authors:  Harubumi Kato; Yukito Ichinose; Morio Ohta; Enjo Hata; Noriaki Tsubota; Hirohito Tada; Yoh Watanabe; Hiromi Wada; Masahiro Tsuboi; Nobuyuki Hamajima; Mitsuo Ohta
Journal:  N Engl J Med       Date:  2004-04-22       Impact factor: 91.245

2.  Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  David S Ettinger; Douglas E Wood; Dara L Aisner; Wallace Akerley; Jessica Bauman; Lucian R Chirieac; Thomas A D'Amico; Malcolm M DeCamp; Thomas J Dilling; Michael Dobelbower; Robert C Doebele; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Ritsuko Komaki; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Leah J Leisch; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

3.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Authors:  Gary M Strauss; James E Herndon; Michael A Maddaus; David W Johnstone; Elizabeth A Johnson; David H Harpole; Heidi H Gillenwater; Dorothy M Watson; David J Sugarbaker; Richard L Schilsky; Everett E Vokes; Mark R Green
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

4.  Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.

Authors:  Giorgio V Scagliotti; Ugo Pastorino; Johan F Vansteenkiste; Lorenzo Spaggiari; Francesco Facciolo; Tadeusz M Orlowski; Luigi Maiorino; Martin Hetzel; Monika Leschinger; Carla Visseren-Grul; Valter Torri
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

Review 5.  Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy.

Authors:  Marco Tazza; Giulio Metro
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

6.  Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.

Authors:  D Waller; M D Peake; R J Stephens; N H Gower; R Milroy; M K B Parmar; R M Rudd; S G Spiro
Journal:  Eur J Cardiothorac Surg       Date:  2004-07       Impact factor: 4.191

7.  Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Authors:  Glenwood D Goss; Chris O'Callaghan; Ian Lorimer; Ming-Sound Tsao; Gregory A Masters; James Jett; Martin J Edelman; Rogerio Lilenbaum; Hak Choy; Fadlo Khuri; Katherine Pisters; David Gandara; Kemp Kernstine; Charles Butts; Jonathan Noble; Thomas A Hensing; Kendrith Rowland; Joan Schiller; Keyue Ding; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

8.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Qing Zhou; Yi-Long Wu
Journal:  Lancet Oncol       Date:  2017-11-21       Impact factor: 41.316

10.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.